AGN News and Press, Allergan plc From 07/18/19

THOUSAND OAKS, Calif. , July 18, 2019 /PRNewswire/ -- Amgen (NASDAQ:AMGN) and Allergan plc (NYSE:AGN) today announced that MVASI™ (bevacizumab-awwb), a biosimilar to Avastin ® (bevacizumab), and KANJINTI TM (trastuzumab-anns), a biosimilar to Herceptin ® (trastuzu...

Outlook Therapeutics (NASDAQ: OTLK ) initiated with Buy rating and $8 (310% upside) at H.C. Wainwright. Shares up  11%  premarket. More news on: Outlook Therapeutics, Inc., Blueprint Medicines Corporation, Deciphera Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the mov...

Damages estimated at $625 million, $1.9 billion after trebling, according to judge’s order A federal judge yesterday greenlighted a class-action lawsuit against Allergan subsidiaries Warner Chilcott and Watson for overcharging direct purchasers for Loestrin 24, Minastrin and g...

Read more ...

Read more ...

With several licenses acquired from well-known pharmaceutical companies, Mirum Pharmaceuticals ( MIRM ) is a name to be followed carefully after the IPO. The most appealing is its pipeline. The company owns two product candidates at Phase 3 of development and several candidates at Phase 2 of d...

DUBLIN , July 17, 2019 /PRNewswire/ -- Allergan plc (NYSE: AGN), a leading global pharmaceutical company with more than 70 years of heritage in eye care, today announced that the U.S. Food and Drug Administration (FDA) has accepted the company's New Drug Application (NDA) for Bimatoprost ...

This article series provides a monthly dashboard of industries in each sector of the GICS classification. It compares valuation and quality factors relative to their historical averages. Executive summary Biotechnology looks undervalued relative to its historical averages in the 3 valuat...

Digital technologies are transforming entire industries, and the field of life sciences is no exception. Health wearables that help us monitor vital signs at home; DNA and genome sequencing that have opened the way to precision medicine; and the increased accessibility to medical data made pos...

Millendo Therapeutics (NASDAQ: MLND ) initiated with Outperform rating and $26 (141% upside) at Oppenheimer. More news on: Viking Therapeutics, Inc., Millendo Therapeutics, Inc., Laboratory Corporation of America Holdings, Healthcare stocks news, Stocks on the move, , Read more ...